Lowering insulin
Pro Research Analysisby 
Searched over 200M research papers for "lowering insulin"
Strategies for Lowering Insulin Levels: Insights from Recent Research
Insulin Administration Routes and Glucose-Lowering Effects
Intravenous, Intramuscular, and Subcutaneous Insulin Administration
Research comparing the glucose-lowering effects of insulin administered via different routes—intravenous (IV), intramuscular (IM), and subcutaneous (SC)—in obese and lean nonketotic diabetic patients reveals that while IV insulin results in a more rapid initial decline in plasma glucose, the overall glucose-lowering effect over a four-hour period is similar across all three methods . This suggests that the choice of administration route can be tailored based on the need for rapid glucose reduction versus sustained control.
Variability in Glucose-Lowering Effects of Different Insulin Types
Insulin Degludec vs. Insulin Glargine
Insulin degludec (IDeg) has been shown to have significantly lower day-to-day and within-day variability in glucose-lowering effects compared to insulin glargine (IGlar) at both 100 U/mL and 300 U/mL concentrations. This consistency in glucose control makes IDeg a preferable option for patients requiring stable insulin levels .
Adjunct Therapies to Insulin in Diabetes Management
Type 1 Diabetes: Beyond Insulin
In Type 1 diabetes (T1D), adjunct glucose-lowering agents, typically used in Type 2 diabetes (T2D), have shown promise in reducing HbA1c levels, lowering insulin requirements, and improving cardiovascular risk factors. These agents include GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which can be beneficial in managing weight and cardiovascular health in T1D patients .
Type 2 Diabetes: Combining Insulin with Oral Glucose-Lowering Drugs
For Type 2 diabetes (T2D), combining continuous subcutaneous insulin infusion (CSII) with oral glucose-lowering drugs such as metformin, GLP-1 receptor agonists, and DPP-4 inhibitors has been found to improve clinical outcomes. Specifically, CSII combined with metformin is most effective in controlling fasting blood glucose and improving insulin resistance, while CSII with DPP-4 inhibitors is best for reducing glycosylated hemoglobin levels .
Insulin Dosing in Diabetic Ketoacidosis
Low-Dose vs. Standard-Dose Insulin
In pediatric diabetic ketoacidosis (DKA), low-dose insulin (0.05 U/kg per hour) has been found to be as effective as the standard dose (0.1 U/kg per hour) in lowering blood glucose levels and resolving acidosis. Additionally, the lower dose is associated with fewer incidences of hypokalemia and hypoglycemia, making it a safer option for initial DKA management .
Basal Insulin Analogues in Type 2 Diabetes
Insulin Detemir vs. Insulin Glargine
A 52-week study comparing insulin detemir and insulin glargine as add-ons to oral glucose-lowering drugs in insulin-naive T2D patients found both to be effective in improving glycemic control with low risk of hypoglycemia. However, insulin detemir was associated with modestly reduced weight gain compared to insulin glargine, particularly in patients on once-daily dosing .
Role of Brain Insulin Action
Hypothalamic Insulin Signaling
Insulin action in the brain, particularly via the hypothalamic insulin receptor substrate-phosphatidylinositol 3-kinase (IRS-PI3K) pathway, plays a significant role in glucose-lowering during insulin treatment. Enhancing hypothalamic PI3K signaling can significantly improve the glycemic response to insulin, highlighting the importance of central insulin action in diabetes management .
Impact of Free Fatty Acid Reduction
Acipimox and Insulin Resistance
Lowering plasma free fatty acid (FFA) levels with Acipimox has been shown to improve insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. This reduction in FFAs leads to decreased plasma insulin levels and enhanced insulin-stimulated glucose uptake, suggesting that targeting FFAs can be an effective strategy in managing insulin resistance .
Conclusion
The research highlights various strategies for lowering insulin levels and improving glucose control, including optimizing insulin administration routes, utilizing adjunct therapies, adjusting insulin dosing in specific conditions, and targeting central insulin action and FFAs. These insights can guide personalized diabetes management to achieve better clinical outcomes.
Sources and full results
Most relevant research papers on this topic